期刊文献+

多西紫杉醇联合顺铂治疗原发灶不明癌的疗效观察 被引量:5

Therapeutic effect of combination of docetaxel and cisplatin in patients with unknown primary cancer
下载PDF
导出
摘要 目的:分析多西紫杉醇联合顺铂治疗原发灶不明癌的疗效。方法:回顾性分析了2004年1月至2008年2月期间收治的15例原发灶不明癌患者,均未经过化疗,PS评分0-2,有可测量病灶,无器官功能障碍。方案:多西紫杉醇60mg/m2,d1;顺铂80mg/m2,d2,静脉化疗,每21天为一个周期,每2个周期后评价疗效。病情未出现进展者共完成4-6个周期。结果:15例患者中有1例因经济原因仅化疗1个周期,其余14例患者总有效率为50%,95%可信区间23%-77%,疾病控制率为78.6%,95%可信区间49%-98%;中位进展时间为5.5个月,中位生存时间为11.6个月;无化疗相关性死亡,常见的不良反应为白细胞减少(1-3级13人),恶心呕吐(1-2级11人),肾毒性(1-2级3人),外周神经毒性(1级3人),肝脏毒性(1-2级,3人),心脏毒性(1级1人)。结论:多西紫杉醇联合顺铂治疗原发灶不明转移癌安全有效,不良反应可以耐受。 Objective:To evaluate the therapeutic effect of docetaxel and cisplatin in the treatment of unknown primary cancer.Methods:To retrospectively analysise 15 with patients carcinoma in an unknown primary organ,no prior chemotherapy.Docetaxel(60 mg/m2) followed by cisplatin(80 mg/m2) was administered intravenously every 21 days.Patients were assessed for tumor response after 2 cycles of chemotherapy,and 4-6 cycles were administered unless disease progression was demonstrated.Results:Among 15 patients enrolled,1 patient abandoned treatment after 1 cycle of chemotherapy,overall response rate was 50%,95% confidence interval: 23%-77%,clinical disease control rate was 78.6%,95% confidence interval: 49%-98%;The median time to progression was 5.5 months.The median survival time was 11.6 months.No treatment-related deaths were observed.Commonly observed side effects included neutropenia(grade 1-3,13 patients),nausea and vomitting(grade 1-2,11 patients),nephrotoxicity(grade1-2,3 patients),neurovirulence(grade 1,3 patients),hepatotoxicity(grade1-2,3 patients),and cardiotoxicity(grade1,1 patients).Conclusion:These results indicate that the combination of docetaxel and cisplatin is a safe and effective regimen for patients with unknown primary cancer,and the toxicity can be tolerated.
作者 崔艳艳
出处 《现代肿瘤医学》 CAS 2010年第10期2057-2058,共2页 Journal of Modern Oncology
关键词 原发灶不明癌 多西紫杉醇 顺铂 化疗 unknown primary cancer docetaxel cisplatin chemotherapy
  • 相关文献

参考文献8

  • 1Pavlidis N,Fizazi K.Cancer of unknown primary(CUP)[J].Crit Rev Oncol Hematol,2005,54(3):243-250.
  • 2Shaw PHS,Adams R,Jordan C,et al.A clinical review of the investigation and management of carcinoma of unknown primary in a single cancer network[J].Clin Oncol,2007,19(1):87-95.
  • 3郭伟剑,张廷.原发灶不明的转移性肝癌的诊治体会[J].实用癌症杂志,1997,12(4):283-285. 被引量:3
  • 4吴毅.原发灶不明颈部转移性鳞癌的诊治[J].中华肿瘤防治杂志,2006,13(12):881-883. 被引量:9
  • 5周艳明,阿地力.莫明.颈部转移癌106例回顾分析[J].新疆医科大学学报,2008,31(3):305-307. 被引量:7
  • 6Park YH,Ryoo BY,Choi SJ,et al.A phaseⅡstudy of paclitaxal plus cisplatin chemotherapy in an unfavourable group of patients with cancer of unknown primary site[J].Jpn J Clin Oncol,2004,34(11):681-685.
  • 7陈华,黄建瑾.原发灶不明癌24例临床分析[J].中国实用医药,2007,2(36):39-41. 被引量:5
  • 8Thom I,Rogers C,Andritzky B,et al.Single-center management of 136 patients with cancer of unknown primary site (CUP syndrome) over a period of 10 years[J].Onkologie,2009,32 (12):741-746.

二级参考文献22

共引文献16

同被引文献29

  • 1陈华,黄建瑾.原发灶不明癌24例临床分析[J].中国实用医药,2007,2(36):39-41. 被引量:5
  • 2杨林,王金万,孙燕,朱允中,刘晓晴,李维廉,邸立军,李佩文,王友良,宋恕平,姚晨,游丽芬.重组人血管内皮抑制素YH-16治疗晚期非小细胞肺癌的临床研究[J].中华肿瘤杂志,2006,28(2):138-141. 被引量:144
  • 3Mevio E, Gorini E, Sbrocca M, et al. The role of positron e- mission tomography (PET) in the management of cervical lymph nodes metastases from an unknown primary turnout. Acta Otorhinolaryngol Ital, 2004, 24(6): 342-347.
  • 4Pavlidis N,Fizazi K. Cancer of unknown primary(CUP). Crit Rev Oncol Heraatol, 2005,54 (3) : 243-250.
  • 5Van de Wouw AJ ,Janssen-Heijnen ML, Coebergh JW, et al. Epidemiology of unknown primary tumours: incidence and population-based survival of 1285 patients in Southeast Neth- erlands,1984-1992. Eur J Cancer,2002,38(3) :409-413.
  • 6Shaw PHS,Adams R,Jordan C,et al. A clinical review of the investigation and management of carcinoma of unknown pri- mary in asingle cancer network. Clin Oncol, 2007,19 ( 1 ) : 87- 95.
  • 7Vant-Veer LJ,Weigelt B. Road map to metastasis. Nat Med, 2003,9 (8) : 999-1000.
  • 8Bugat R, Bataillard A, Lesimple T, et al. Summary of the standards,options and recommendations for the management of patients with carcinoma of unknown primary site. Br J Cancer, 2003,89 Suppl 1 : $59-$66.
  • 9Greco FA, Burris HA, Erland EB, et al. Carcinoma of un- known primary site. Long term follow-up after treatment with paclitaxe| earboplatin and etoposide. Cancer, 2000, 89 26552660.
  • 10Park YH,Ryoo BY,Choi SJ, et al. A Phase II study of paeli- taxel plus cisplatin chemotherapy in an unfavourable group of patients with cancer of unknown primary site. Jpn J Clin 0n- col,2004,34(11) :681-685.

引证文献5

二级引证文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部